240 related articles for article (PubMed ID: 14971738)
21. Acromegaly with apparently normal GH secretion: implications for diagnosis and follow-up.
Dimaraki EV; Jaffe CA; DeMott-Friberg R; Chandler WF; Barkan AL
J Clin Endocrinol Metab; 2002 Aug; 87(8):3537-42. PubMed ID: 12161471
[TBL] [Abstract][Full Text] [Related]
22. Characterization of 24-hour growth hormone secretion in acromegaly: implications for diagnosis and therapy.
Ho KY; Weissberger AJ
Clin Endocrinol (Oxf); 1994 Jul; 41(1):75-83. PubMed ID: 8050134
[TBL] [Abstract][Full Text] [Related]
23. Laboratory investigation of acromegaly: is basal or random GH > 0.4 µg/L in the presence of normal serum IGF-1 an important result?
Rosario PW; Calsolari MR
Arch Endocrinol Metab; 2015 Feb; 59(1):54-8. PubMed ID: 25926115
[TBL] [Abstract][Full Text] [Related]
24. Relationship between disease-related morbidity and biochemical markers of activity in patients with acromegaly.
Puder JJ; Nilavar S; Post KD; Freda PU
J Clin Endocrinol Metab; 2005 Apr; 90(4):1972-8. PubMed ID: 15634715
[TBL] [Abstract][Full Text] [Related]
25. Serum insulin-like growth factor-binding protein-3 levels in the diagnosis of acromegaly.
Grinspoon S; Clemmons D; Swearingen B; Klibanski A
J Clin Endocrinol Metab; 1995 Mar; 80(3):927-32. PubMed ID: 7533774
[TBL] [Abstract][Full Text] [Related]
26. Acromegaly.
Scacchi M; Cavagnini F
Pituitary; 2006; 9(4):297-303. PubMed ID: 17077948
[TBL] [Abstract][Full Text] [Related]
27. Biochemical evidence in favor of revising Cortina criteria.
Webb SM; Sucunza N; Barahona MJ
J Endocrinol Invest; 2005; 28(11 Suppl International):84-6. PubMed ID: 16625854
[TBL] [Abstract][Full Text] [Related]
28. [Growth hormone (GH) and IGF-I assays: methodological aspects and its implications in acromegaly diagnosis and follow-up].
Casagrande A; Czepielewski MA
Arq Bras Endocrinol Metabol; 2007 Jun; 51(4):511-9. PubMed ID: 17684610
[TBL] [Abstract][Full Text] [Related]
29. Outpatient assessment of residual growth hormone secretion in treated acromegaly with overnight urinary growth hormone excretion, random serum growth hormone and insulin like growth factor-1.
Parfitt VJ; Flanagan D; Wood P; Leatherdale BA
Clin Endocrinol (Oxf); 1998 Nov; 49(5):647-52. PubMed ID: 10197081
[TBL] [Abstract][Full Text] [Related]
30. GH and mortality in acromegaly.
Sheppard MC
J Endocrinol Invest; 2005; 28(11 Suppl International):75-7. PubMed ID: 16625851
[TBL] [Abstract][Full Text] [Related]
31. Predictors of the outcome of surgical treatment in acromegaly and the value of the mean growth hormone day curve in assessing postoperative disease activity.
Kaltsas GA; Isidori AM; Florakis D; Trainer PJ; Camacho-Hubner C; Afshar F; Sabin I; Jenkins JP; Chew SL; Monson JP; Besser GM; Grossman AB
J Clin Endocrinol Metab; 2001 Apr; 86(4):1645-52. PubMed ID: 11297598
[TBL] [Abstract][Full Text] [Related]
32. Low insulin resistance after surgery predicts poor GH suppression one year after complete resection for acromegaly: a retrospective study.
Edo N; Morita K; Suzuki H; Takeshita A; Miyakawa M; Fukuhara N; Nishioka H; Yamada S; Takeuchi Y
Endocr J; 2016 May; 63(5):469-77. PubMed ID: 26949262
[TBL] [Abstract][Full Text] [Related]
33. Biochemical evidence supporting the Cortina criteria.
von Werder K
J Endocrinol Invest; 2005; 28(11 Suppl International):81-3. PubMed ID: 16625853
[TBL] [Abstract][Full Text] [Related]
34. [Lowered ghrelin levels in acromegaly—normalization after treatment].
Kozakowski J; Rabijewski M; Zgliczyński W
Endokrynol Pol; 2005; 56(6):862-70. PubMed ID: 16821203
[TBL] [Abstract][Full Text] [Related]
35. Monitoring disease activity using GH and IGF-I in the follow-up of 501 patients with acromegaly.
Sherlock M; Aragon Alonso A; Reulen RC; Ayuk J; Clayton RN; Holder G; Sheppard MC; Bates A; Stewart PM
Clin Endocrinol (Oxf); 2009 Jul; 71(1):74-81. PubMed ID: 19178529
[TBL] [Abstract][Full Text] [Related]
36. Value of early postoperative random growth hormone levels and nadir growth hormone levels after oral glucose tolerance testing in acromegaly.
Rotermund R; Burkhardt T; Rohani Z; Jung R; Aberle J; Flitsch J
Growth Horm IGF Res; 2018 Aug; 41():64-70. PubMed ID: 29555234
[TBL] [Abstract][Full Text] [Related]
37. Acromegaly with normal IGF-1 levels probably due to poorly controlled diabetes mellitus.
Arihara Z; Sakurai K; Yamada S; Murakami O; Takahashi K
Tohoku J Exp Med; 2008 Dec; 216(4):325-9. PubMed ID: 19060447
[TBL] [Abstract][Full Text] [Related]
38. Usefulness of different biochemical markers of the insulin-like growth factor (IGF) family in diagnosing growth hormone excess and deficiency in adults.
Marzullo P; Di Somma C; Pratt KL; Khosravi J; Diamandis A; Lombardi G; Colao A; Rosenfeld RG
J Clin Endocrinol Metab; 2001 Jul; 86(7):3001-8. PubMed ID: 11443159
[TBL] [Abstract][Full Text] [Related]
39. Is GH nadir during OGTT a reliable test for diagnosis of acromegaly in patients with abnormal glucose metabolism?
Dobri G; Niwattisaiwong S; Bena JF; Gupta M; Kirwan J; Kennedy L; Hamrahian AH
Endocrine; 2019 Apr; 64(1):139-146. PubMed ID: 30415402
[TBL] [Abstract][Full Text] [Related]
40. Clinical features and natural course of acromegaly in patients with discordance in the nadir GH level on the oral glucose test and the IGF-1 value at 3 months after adenomectomy.
Kinoshita Y; Tominaga A; Usui S; Arita K; Sakoguchi T; Sugiyama K; Kurisu K
Neurosurg Rev; 2016 Apr; 39(2):313-8; discussion 318-9. PubMed ID: 26785642
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
